Precigen, Inc., a biopharmaceutical company operating within the Health Care sector, specifically in the Biotechnology industry, has been making significant strides in the development of gene and cell therapies. The company’s focus is on addressing a range of health issues, including immuno-oncology, autoimmune disorders, and infections. With its headquarters in Germantown, United States, Precigen, Inc. operates on a global scale, aiming to revolutionize the healthcare industry through innovative solutions.
As of September 28, 2026, Precigen, Inc. was listed on the Nasdaq with a close price of $8.05 per share. The company’s stock has experienced fluctuations over the past year, reaching a 52-week high of $8.27 on September 24, 2026, and a 52-week low of $2.99 on October 9, 2025. These figures reflect the dynamic nature of the biotechnology sector and the market’s response to the company’s ongoing research and development efforts.
With a market capitalization of $2.8 billion, Precigen, Inc. holds a significant position within the biotechnology industry. However, the company’s price-to-earnings ratio stands at -7.92, indicating that it is currently not generating positive earnings. This is not uncommon in the biotechnology sector, where companies often invest heavily in research and development, leading to periods of negative earnings as they work towards bringing innovative therapies to market.
Precigen, Inc.’s mission is to transform the healthcare landscape by developing cutting-edge gene and cell therapies. The company’s research efforts are concentrated on immuno-oncology, which involves harnessing the body’s immune system to fight cancer, as well as addressing autoimmune disorders and infections. By focusing on these areas, Precigen, Inc. aims to provide groundbreaking treatments that can significantly improve patient outcomes.
The company’s global operations and commitment to innovation position it as a key player in the biotechnology industry. As Precigen, Inc. continues to advance its research and development initiatives, it remains focused on delivering therapies that have the potential to change the way health issues are treated, ultimately contributing to the broader goal of revolutionizing healthcare.
